Mediclarum
Medicine guide

Dextrose

25 g/50mL · Injection, Solution

  • Prescription only
Active substance
Dextrose Monohydrate
Made by
ProPharma Distribution

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

At a glance

Quoted from the official label · 2025-07-18

The FDA lists a current shortage of dextrose monohydrate

Not necessarily this product — shortages are reported per presentation. Your pharmacy will know. · Updated 2026-09-22 FDA drug shortages

Used for
  • 50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels.
The label’s usual adult dose

The maximum rate at which dextrose can be infused without producing glycosuria is 0.5 g/kg of body weight/hour.

Full directions ↓
Do not take it if

A concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present, nor in the presence of delirium tremens if the patient is already dehydrated.

All warnings ↓
Good to know
  • Prescription only
  • FDA enforcement reports list no ongoing recall, and none from the last two years, for this product code · checked 2026-10-02
34other products contain Dextrose Monohydrate — compare makers, forms and strengths

Every line above is selected, not written, from the official label. Nothing is reworded. DailyMed

What it is for

  • 50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels.
  • The solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements.
  • Slow infusion of hypertonic solutions is essential to ensure proper utilization of dextrose and
  • avoid production of hyperglycemia.

From the official label · 2025-07-18 · DailyMed

How it works

From this product’s own US prescribing label.

When administered intravenously this solution restores blood glucose levels in hypoglycemia and provides a source of carbohydrate calories.

Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein-sparing action.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-07-18

Do not take it if

  • A concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present, nor in the presence of delirium tremens if the patient is already dehydrated.
  • Dextrose injection without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

  • For peripheral vein administration: Injection of the solution should be made slowly .
  • The maximum rate at which dextrose can be infused without producing glycosuria is 0.5 g/kg of body weight/hour.
  • About 95% of the dextrose is retained when infused at a rate of 0.8 g/kg/hr.
  • In insulin-induced hypoglycemia, intravenous injection of 10 to 25 grams of dextrose (20 to 50 mL of 50% dextrose) is usually adequate.
  • Repeated doses and supportive treatment may be required in severe cases.
  • A specimen for blood glucose determination should be taken before injecting the dextrose.
  • In such emergencies, dextrose should be administered promptly without awaiting pretreatment test results.
  • For central venous administration:
  • For total parenteral nutrition 50% Dextrose Injection, USP is administered by slow intravenous infusion (a) after admixture with amino acid solutions via an indwelling catheter with the tip positioned in a large central vein, preferably the superior vena cava, or (b) after dilution with sterile water for injection.
  • Dosage should be adjusted to meet individual patient requirements.
  • Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.
  • The maximum rate of dextrose administration which does not result in glycosuria is the same as cited above.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
  • See CONTRAINDICATIONS .

Quoted from the official label, section “Dosage & Administration”.

Other warnings

  • 50% Dextrose Injection is hypertonic and may cause phlebitis and thrombosis at the site of injection.
  • Significant hyperglycemia and possible hyperosmolar syndrome may result from too rapid administration.
  • The physician should be aware of the symptoms of hyperosmolar syndrome, such as mental confusion and loss of consciousness, especially in patients with chronic uremia and those with known carbohydrate intolerance.
  • The intravenous administration of this solution can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.
  • Additives may be incompatible.
  • Consult with pharmacist if available.
  • When introducing additives, use aseptic technique, mix thoroughly and do not store.
  • The solution should be given slowly, preferably through a small-bore needle into a large vein, to minimize venous irritation.
  • Concentrated dextrose should be administered via central vein only after suitable dilution.
  • Do not use unless the solution is clear and seal is intact.
  • Discard unused portion.
  • Electrolyte deficits, particularly in serum potassium and phosphate, may occur during prolonged use of concentrated dextrose solutions.
  • Blood electrolyte monitoring is essential and fluid and electrolyte imbalances should be corrected.
  • Essential vitamins and minerals also should be provided as needed.
  • To minimize hyperglycemia and consequent glycosuria, it is desirable to monitor blood and urine glucose and if necessary, add insulin.
  • When a concentrated dextrose infusion is abruptly withdrawn, it is advisable to follow with the administration of 5% or 10% dextrose injection to
  • avoid rebound hypoglycemia.
  • Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.
  • Care should be exercised to ensure that the needle is well within the lumen of the vein and that extravasation does not occur.
  • If thrombosis should occur during administration, the injection should be stopped and corrective measures instituted.
  • Concentrated dextrose solutions should not be administered subcutaneously or intramuscularly.
  • Carcinogenesis, Mutagenesis, Impairment of Fertility:
  • Studies with solutions in polypropylene syringes have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.
  • Pregnancy: Animal reproduction studies have not been conducted with dextrose.
  • Nursing Mothers It is not known whether this drug is excreted in human milk.

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

  • Animal reproduction studies have not been conducted with dextrose.
  • It is also not known whether dextrose can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
  • Dextrose should be given to a pregnant woman only if clearly needed.
  • It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when 50% Dextrose Injection, USP is administered to a nursing mother.

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

In the event of overhydration or solute overload during therapy, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS and PRECAUTIONS .

Quoted from the official label, section “Overdosage”.

Side effects

  • Hyperosmolar syndrome, resulting from excessively rapid administration of concentrated dextrose may cause mental confusion and/or loss of consciousness.
  • Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
  • If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

Quoted from the official label, section “Adverse Reactions”.

What it looks like and how it is packed

  • 50% Dextrose Injection, USP is supplied in single-dose containers as follows:
  • NDC 84549-517-16 1 - 50 mL Ansyr ®II Plastic Syringe with syringe and barrel detached 25 g/50 mL (0.5 g/mL) Exposure of pharmaceutical products to heat should be minimized.
  • Avoid excessive heat.
  • Protect from freezing.
  • Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

Quoted from the official label, section “How Supplied”.

How to store it

  • Exposure of pharmaceutical products to heat should be minimized.
  • Avoid excessive heat. Protect from freezing.
  • Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

Quoted from the official label, section “Storage and Handling”.

What is in it

  • 50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for injection for intravenous injection as a fluid and nutrient replenisher.
  • Each mL of fluid contains 0.5 g dextrose, hydrous which delivers 3.4 kcal/gram.
  • The solution has an osmolarity of 2.53 mOsmol/mL (calc.), pH 3.2 to 6.5 and may contain sodium hydroxide and/or hydrochloric acid for pH adjustment.
  • The solution contains no bacteriostat, antimicrobial agent or added buffer (except for pH adjustment) and is intended only for use as a single-dose injection.
  • When smaller doses are required, the unused portion should be discarded with the entire unit.
  • Dextrose, USP is chemically designated C 6 H 12 O 6 ∙ H 2 O (D-glucose monohydrate), a hexose sugar freely soluble in water.
  • Dextrose, hydrous has the following structural formula:
  • Water for Injection, USP is chemically designated H 2 O.
  • The syringe is molded from a specially formulated polypropylene.
  • Water permeates from inside the container at an extremely slow rate which will have an insignificant effect on solution concentration over the expected shelf life.
  • Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the syringe material.
  • Chemical Structure

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

The stored label for this product has no list of inactive ingredients. The list on the pack is the one to check.

Quoted from the FDA label. A label that does not name an ingredient is not a guarantee that the product is free of it, and formulations change. With an allergy, check the pack and ask a pharmacist.

Every version of this medicine (9)

The same active substance, strength and kind of form, from every company that sells it — with what each label lists.

Showing 9 of 9

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

CanadaNo exact match for this strength and form

Every strength and form (14)

Details

Made byProPharma Distribution
Active substanceDextrose Monohydrate
Strength25 g/50mL
FormInjection, Solution
RouteIntravenous
Packs50 mL in 1 SYRINGE, PLASTIC
NDC84549-517

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

42 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

Dextrose50 g/1000mLPrescription onlyInjection, Solution Baxter Healthcare Corporation · Dextrose MonohydrateDextrose100 g/1000mLPrescription onlyInjection, Solution Baxter Healthcare Corporation · Dextrose MonohydrateDextrose5 g/100mLPrescription onlyInjection, Solution Baxter Healthcare Corporation · Dextrose MonohydrateDextrose2.5 g/50mLPrescription onlyInjection Baxter Healthcare Company · Dextrose MonohydrateDextrose5 g/100mLPrescription onlyInjection Baxter Healthcare Company · Dextrose MonohydrateDextrose2.5 g/50mLPrescription onlyInjection Baxter Healthcare Corporation · Dextrose Monohydrate

See every product with Dextrose Monohydrate